0000000001246233

AUTHOR

A Padovani

showing 7 related works from this author

Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.

2001

BACKGROUND:Amyloid precursor protein (APP) forms with apparent molecular weights of 130, 110, and 106 kd are present in human platelets. It has been demonstrated that Alzheimer disease (AD) is specifically associated with a decreased APP forms ratio in platelets. OBJECTIVE:To investigate whether acetylcholinesterase (AChE) inhibitor treatment modifies the ratio of platelet APP forms in patients with AD. PATIENTS AND METHODS:From a large sample of patients with probable AD, 30 with mild to moderate AD were selected. Each patient underwent a clinical evaluation including the Mini-Mental State Examination (MMSE) and platelet APP forms analysis at baseline and after 30 days. During this interva…

Blood PlateletsMalemedicine.medical_specialtyIsoformmedicine.drug_classBlotting WesternAlzheimer disease; biomarker; platelet; Amyloid Precursor Protein; Isoformchemistry.chemical_compoundAmyloid beta-Protein PrecursorArts and Humanities (miscellaneous)PiperidinesDonepezil HydrochlorideInternal medicinemental disordersAmyloid precursor proteinMedicineHumansPlateletDonepezilLongitudinal StudiesDonepezilCholinesteraseAgedamyloid alzheimer diseaseplateletbiologybusiness.industryMiddle AgedAcetylcholinesteraseEndocrinologychemistryAcetylcholinesterase inhibitorEnzyme inhibitorIndansAmyloid Precursor Proteinbiology.proteinbiomarkerSettore MED/26 - NeurologiaFemaleNeurology (clinical)Cholinesterase InhibitorsAlzheimer diseasebusinessmedicine.drugFollow-Up Studies
researchProduct

Innate immunity but not NLRP3 inflammasome activation correlates with severity of stable COPD.

2014

Background In models of COPD, environmental stressors induce innate immune responses, inflammasome activation and inflammation. However, the interaction between these responses and their role in driving pulmonary inflammation in stable COPD is unknown. Objectives To investigate the activation of innate immunity and inflammasome pathways in the bronchial mucosa and bronchoalveolar lavage (BAL) of patients with stable COPD of different severity and control healthy smokers and non-smokers. Methods Innate immune mediators (interleukin (IL)-6, IL-7, IL-10, IL-27, IL-37, thymic stromal lymphopoietin (TSLP), interferon γ and their receptors, STAT1 and pSTAT1) and inflammasome components (NLRP3, NA…

EXPRESSIONMaleINTERLEUKIN-6InflammasomesCOPD PathologyChronic Obstructive Pulmonary DiseaseRespiratory SystemImmunity NLRP3 COPDBronchiReceptors Cell SurfaceRespiratory MucosaPULMONARYInterferon-gammaPulmonary Disease Chronic ObstructiveMARKERSThymic Stromal LymphopoietinSPUTUMNLR Family Pyrin Domain-Containing 3 ProteinCytokine Receptor gp130Humans1506HMGB1 ProteinAdaptor Proteins Signal TransducingAgedScience & TechnologyRECEPTORInterleukinsSmoking1103 Clinical SciencesMiddle AgedInterleukin-1 Receptor-Like 1 ProteinImmunity InnateInnate Immunityrespiratory tract diseasesANTIINFLAMMATORY CYTOKINESTAT1 Transcription FactorCase-Control StudiesT-CELLSASTHMACytokinesFemaleCOPD Pathology Innate ImmunityCarrier ProteinsLife Sciences & BiomedicineBronchoalveolar Lavage FluidSMOKERSThorax
researchProduct

The association between low skeletal muscle mass and delirium: results from the nationwide multi-centre Italian Delirium Day 2017

2021

Abstract Introduction Delirium and sarcopenia are common, although underdiagnosed, geriatric syndromes. Several pathological mechanisms can link delirium and low skeletal muscle mass, but few studies have investigated their association. We aimed to investigate (1) the association between delirium and low skeletal muscle mass and (2) the possible role of calf circumference mass in finding cases with delirium. Methods The analyses were conducted employing the cross-sectional “Delirium Day” initiative, on patient 65 years and older admitted to acute hospital medical wards, emergency departments, rehabilitation wards, nursing homes and hospices in Italy in 2017. Delirium was diagnosed as a 4 + …

MaleAgingmedicine.medical_specialtySarcopeniamedicine.medical_treatmentSocio-culturaleOlder personLogistic regressionDelirium Older persons Sarcopenia.Internal medicinemental disordersDelirium; Older persons; SarcopeniamedicineDementiaHumansLS4_4Muscle SkeletalPathologicalAgedRehabilitationbusiness.industryArea under the curveDeliriumSettore MED/23 - Chirurgia CardiacaSkeletalmedicine.diseaseSkeletal muscle massCross-Sectional StudiesItalyOlder personsSarcopeniaDeliriumMuscleFemaleDelirium; Older persons; Sarcopenia; Aged; Cross-Sectional Studies; Female; Humans; Italy; Male; Muscle Skeletal; Delirium; SarcopeniaGeriatrics and Gerontologymedicine.symptombusiness
researchProduct

Prevalence and features of delirium in older patients admitted to rehabilitation facilities

2022

Background: Delirium is thought to be common across various settings of care; however, still little research has been conducted in rehabilitation. Aim: We investigated the prevalence of delirium, its features and motor subtypes in older patients admitted to rehabilitation facilities during the three editions of the “Delirium Day project”. Methods: We conducted a cross-sectional study in which 1237 older patients (age ≥ 65 years old) admitted to 50 Italian rehabilitation wards during the three editions of the “Delirium Day project” (2015 to 2017) were included. Delirium was evaluated through the 4AT and its motor subtype with the Delirium Motor Subtype Scale. Results: Delirium was detected i…

AgingDisabilityRehabilitationDeliriumDelirium; Dementia; Disability; Physical restraint; RehabilitationCross-Sectional StudiesActivities of Daily Livingmental disordersPrevalenceHumansDementiaPhysical restraintGeriatrics and GerontologyAgedAging Clinical and Experimental Research
researchProduct

Understanding Factors Associated With Psychomotor Subtypes of Delirium in Older Inpatients With Dementia

2020

Objectives Few studies have analyzed factors associated with delirium subtypes. In this study, we investigate factors associated with subtypes of delirium only in patients with dementia to provide insights on the possible prevention and treatments. Design This is a cross-sectional study nested in the "Delirium Day" study, a nationwide Italian point-prevalence study. Setting and participants Older patients admitted to 205 acute and 92 rehabilitation hospital wards. Measures Delirium was evaluated with the 4-AT and the motor subtypes with the Delirium Motor Subtype Scale. Dementia was defined by the presence of a documented diagnosis in the medical records and/or prescription of acetylcholine…

Rehabilitation hospitalmedicine.medical_specialtyUrinary systemSocio-culturaledementia; elderly; Motor subtypes of delirium; Aged; Cross-Sectional Studies; Humans; Inpatients; Italy; Delirium; Dementiaelderly03 medical and health sciences0302 clinical medicineInternal medicinemental disordersmedicineDementiaMotor subtypes of delirium dementia elderlyHumansdementia elderly Motor subtypes of delirium030212 general & internal medicineLS4_4Medical prescriptionGeneral NursingAgedPsychomotor learningInpatientsbusiness.industryHealth PolicyMedical recordMotor subtypes of deliriumMemantineDeliriumGeneral Medicinemedicine.diseasedementia; elderly; Motor subtypes of deliriumSettore MED/26 - NEUROLOGIACross-Sectional StudiesItalyDeliriumDementiaGeriatrics and Gerontologymedicine.symptombusiness030217 neurology & neurosurgerymedicine.drug
researchProduct

When the amnestic mild cognitive impairment disappears: characterisation of the memory profile

2009

BACKGROUND/OBJECTIVES: Subjects affected by mild cognitive impairment (MCI) may improve during the observation period. This is the first study investigating qualitative features of memory deficits in subjects affected by reversible MCI [reversible cognitive impairment (RCI)]. METHODS: Baseline cognitive and memory performances of 18 subjects affected by amnestic MCI who had normalized cognitive performances at follow-ups were compared with those of 76 amnestic MCI subjects who still showed impaired cognitive performances at the 24-month follow-up (MCI) and with those of a group of 87 matched control subjects (normal controls). RESULTS: Compared with normal controls the memory deficit in the…

MalememorianeuropsychologyAudiologyNeuropsychological TestsAlzheimer diseaseMemoryMild cognitive impairmentNeuropsychologyPreclinical dementiadeterioramento cognitivo lieveLong-term memoryCognitive disorderNeuropsychologypreclinical dementiaCognitionGeneral MedicinePsychiatry and Mental healthNeuropsychology and Physiological PsychologyMemory Short-TermDisease ProgressionFemaleSettore MED/26 - Neurologiamedicine.symptomAlzheimer's diseasePsychologymedicine.medical_specialtyCognitive NeuroscienceAmnesiaHumans; Alzheimer Disease; Disease Progression; Aged; Mental Recall; Cognition Disorders; Memory; Memory Short-Term; Recognition (Psychology); Psychomotor Performance; Follow-Up Studies; Neuropsychological Tests; Amnesia; Female; MaleRecognition (Psychology)M-PSI/02 - PSICOBIOLOGIA E PSICOLOGIA FISIOLOGICAbehavioral disciplines and activitiesmild cognitive impairmentAlzheimer DiseaseMemorymental disordersNeuropsychologiamedicineHumansMemory disorderAgedMED/26 - NEUROLOGIARecognition Psychologymedicine.diseaseMCInervous system diseasesShort-TermMental Recallmild cognitive impairment; neuropsychology; memory; preclinical dementia; Alzheimer diseaseAmnesiaMED/09 - MEDICINA INTERNACognition Disordershuman activitiesNeurosciencePsychomotor PerformanceFollow-Up Studies
researchProduct

Erythropoietin in amyotrophic lateral sclerosis: a multicentre, randomized, double blind, placebo controlled, phase III study.

2015

Objective To assess the efficacy of recombinant human erythropoietin (rhEPO) in amyotrophic lateral sclerosis (ALS). Methods Patients with probable laboratory-supported, probable or definite ALS were enrolled by 25 Italian centres and randomly assigned (1:1) to receive intravenous rhEPO 40 000 IU or placebo fortnightly as add-on treatment to riluzole 100 mg daily for 12 months. The primary composite outcome was survival, tracheotomy or >23 h non-invasive ventilation (NIV). Secondary outcomes were ALSFRS-R, slow vital capacity (sVC) and quality of life (ALSAQ-40) decline. Tolerability was evaluated analysing adverse events (AEs) causing withdrawal. The randomisation sequence was computer-…

MaleGastroenterologylaw.inventionRandomized controlled triallaw1506Amyotrophic lateral sclerosisMOTOR NEURON DISEASEeducation.field_of_studyRecombinant ProteinMiddle AgedRecombinant ProteinsTreatment OutcomePsychiatry and Mental HealthNeuromuscularSettore MED/26 - NeurologiaFemaleerythropoietyn clinical trialmedicine.drugHumanALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment OutcomeAdultmedicine.medical_specialtyPopulationSocio-culturalePlaceboDouble blindALS; erythropoietyn clinical trialDouble-Blind MethodArts and Humanities (miscellaneous)ALS; MOTOR NEURON DISEASE; Adult; Aged; Amyotrophic Lateral Sclerosis; Double-Blind Method; Epoetin Alfa; Erythropoietin; Female; Humans; Male; Middle Aged; Recombinant Proteins; Treatment Outcome; Neurology (clinical); Psychiatry and Mental Health; Surgery; Arts and Humanities (miscellaneous)Internal medicinemedicineALS; MOTOR NEURON DISEASEHumanseducationErythropoietinAgedbusiness.industryAmyotrophic Lateral SclerosisEpoetin alfamedicine.diseaseSurgeryClinical trialEpoetin AlfaErythropoietinSurgeryNeurology (clinical)ALSbusinessAmyotrophic Lateral Sclerosi
researchProduct